Esperion TherapeuticsESPR
ESPR
About: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Employees: 240
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
41% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $2.19M
11% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 44
4% more funds holding
Funds holding: 175 [Q2] → 182 (+7) [Q3]
5.7% less ownership
Funds ownership: 75.02% [Q2] → 69.32% (-5.7%) [Q3]
31% less capital invested
Capital invested by funds: $316M [Q2] → $217M (-$98.3M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
123%
upside
Avg. target
$8.20
358%
upside
High target
$16
794%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
JMP Securities Roy Buchanan 33% 1-year accuracy 6 / 18 met price target | 291%upside $7 | Market Outperform Reiterated | 23 Jan 2025 |
HC Wainwright & Co. Joseph Pantginis 26% 1-year accuracy 104 / 406 met price target | 794%upside $16 | Buy Reiterated | 23 Jan 2025 |
Goldman Sachs Paul Choi 22% 1-year accuracy 2 / 9 met price target | 123%upside $4 | Neutral Reinstated | 18 Dec 2024 |
Cantor Fitzgerald Kristen Kluska 39% 1-year accuracy 42 / 108 met price target | 347%upside $8 | Overweight Initiated | 17 Dec 2024 |
Needham Serge Belanger 47% 1-year accuracy 60 / 129 met price target | 235%upside $6 | Buy Reiterated | 13 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –
Positive
Seeking Alpha
1 month ago
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational improvements, Ready Capital Corporation faces liquidity risks, and TORM plc is crucial despite energy sector volatility. Esperion Therapeutics' breakout and Cardiff Oncology's promising trial data present compelling buy opportunities, while Advantest Corporation's high valuation suggests caution.
Neutral
GlobeNewsWire
1 month ago
Esperion Announces $210 Million Convertible Debt Financing
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain holders of its outstanding 4.00% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”). Pursuant to the Agreements, Esperion will issue $100 million aggregate principal amount of its 5.75% Convertible Senior Subordinated Notes due 2030 (the “New Notes”) consisting of (a) approximately $57.5 million principal amount of New Notes, along with approximately $153.4 million in cash, issued in exchange for approximately $210.1 million principal amount of the 2025 Notes (the “Exchange Transactions”) and (b) approximately $42.5 million principal amount of New Notes for cash (the “Subscription Transactions”), in each case, pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities Act”).
Neutral
GlobeNewsWire
1 month ago
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years – ANN ARBOR, Mich., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel.
Positive
Seeking Alpha
1 month ago
Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance.
Positive
Zacks Investment Research
1 month ago
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.
Neutral
GlobeNewsWire
2 months ago
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
Positive
Seeking Alpha
2 months ago
Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence.
Neutral
GlobeNewsWire
2 months ago
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Neutral
Seeking Alpha
2 months ago
Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™